Logo
Logo
Main Content Image
Icon

Dr. Reddy's API Manufacturing Capabilities:

Dr. Reddy’s manufactures 250+ APIs across India, Mexico, and the UK, with eight USFDA-inspected cGMP facilities—six in India, one in Mexico, and one in the UK. All facilities comply with ICH Q7 guidelines and are regularly audited by global regulatory authorities including USFDA, EMA, ANVISA, PMDA, Health Canada, and others.

With 40+ years of technical leadership, we specialize in complex APIs such as steroids, peptides, long-chain molecules, and HPAPIs. Our R&D teams develop robust, scalable processes and support customers through dossier filings and commercialization worldwide. 

Dr. Reddy’s API division is strategically working towards becoming the number one API company in the world by focusing on strong innovation, global footprint, and exceptional customer service. As one of the top API manufacturers in USA driven by consistency and the increasing need for good health, we are committed to improving access to our APIs across the  United States.

Reliable, Sustainable Supply Chain

  • Multi-sourced KSMs for supply resilience
  • Stringent quality specifications and timely deliveries
  • Capacity expansion to meet global demand for essential APIs

Dr. Reddy’s combines deep scientific expertise, global compliance, and sustainable manufacturing to be your trusted API partner.

40+ Years of Expertise

Leading supplier of APIs for more than 40 years, with an industry leading portfolio of generic APIs and partner of choice for global formulators.

8 Manufacturing units

We have 8 commercial USFDA inspected API plants/production units, of which 6 are in India and 1 in Uk and 1 in Mexico.

Manufacturing Capacity

Sufficient manufacturing capacity and flexible batch sizes enable fast turnaround times, supported by backward integration and a resilient supply chain to ensure consistent, uninterrupted delivery.

Safety and Compliance

All our plants are operated in accordance with cGMP (ICH Q7a) and are regularly inspected/audited by international authorities and agencies.

Manufacturing Locations

      • Mirfield, UK
      • Cuernavaca, Mexico
      • CTO VI Vizag & CTO-SEZ Vizag
      • CTO - I, II, III, Hyderabad
      • CTO - V (Miryalaguda, Nalgonda)
call big icon

如果您有任何特定国家的需求,我们乐意提供帮助。

Manufacturing Capabilities

  • 250+ APIs
  • 4,100+ KL of reactor volumes.
  • 1250+ Reactors including ~100+ reactors with containment across 4 sites (HPAI /Oncology/ steroids/prostaglandins).
  • 5,000+ MT of Intermediates manufactured.
  • 90% of our API pipeline is forward integrated to generic formulations.
  • 100+ Commercial Molecules
  • 50+ Pipeline molecules (Filed + under development).
  • 2,100+ MT of APIs manufactured.
  • Deep expertise in handing complex peptide molecules.
  • Can handle molecules of OEL up to 0.1 µg/m3 by protecting environment, people & product.

Quality Control

Quality Control Policies

Quality Control Policies

A key component in quality control in pharmaceutical industry is helping customers by providing a quality product. We achieve this by ensuring that all our facilities operate efficiently and to the latest quality, safety, and productivity standards.
At Dr. Reddy’s, quality control is central to our commitment to delivering safe, high-quality APIs. Our facilities operate under cGMP (ICH Q7) standards, ensuring global regulatory compliance and consistent product performance.

Advanced Analytical & Process Excellence

  • Scalable manufacturing for consistent quality
  • Robust analytical methods to eliminate nitrosamine and azido impurities
  • Comprehensive impurity profiling, characterization, and control
  • Use of advanced techniques to define chemical and physical attributes
  • Efficient operations aligned with the latest quality, safety, and productivity standards

Quality Assurance

Quality Assurance

The pharmaceutical quality assurance (QA) team at Dr. Reddy’s continually monitors various facets of the quality management system. We are committed to maintaining highest quality standards in cGMP manufacturing through periodic reviews and continuous improvement of quality management system. All our manufacturing units have undergone multiple cGMP audits by various regulatory authorities, and numerous quality audits by various customers. As a result, our high-quality APIs meets all the formulation needs for various global markets.

Review Meetings for Quality Control

Review Meetings for Quality Control

Dr. Reddy’s maintains a robust quality system through continuous monitoring, cross-functional audits, and harmonized procedures across all API manufacturing units. Every facility operates under cGMP (ICH Q7) and is regularly inspected by global regulatory authorities. 

Recognized for our strong compliance record, we support customers with:

  • DMF, CMC, IND, and NDA filings
  • Deep experience with USFDA, EMA, WHO GMP, PMDA, KFDA, ANVISA, Health Canada, and more

Related Pages

R & D

R & D

particle
Customer Service

Customer Service

particle
Regulatory

Regulatory

particle

免责声明

本網站上的任何信息,包括對任何產品或服務的任何提及,均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是,在某些情況下,雷迪博士可自行決定並根據當地法律要求,在存在此類監管豁免的任何地方,提供此類產品的研究數量,以根據《印度專利法》第 107A 條(Bolar 豁免)進行監管提交。購買者應對其各自市場的產品或服務(包括專利情況)進行獨立評估,並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證,包括但不限於適銷性、適用於特定用途和非侵權的保證。